Phase 1/2 study of cetuximab plus capecitabine in elderly patients with kras-wild type mCRC who have no prior chemotherapy

ABSTRACT: Interventions: capecitabine,cetuximab Primary outcome(s): Safety/efficacy Study Design: Single arm Non-randomized

DISEASE(S): Unresectable Metastatic Colorectal Cancer

PROVIDER: 2620026 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR